Core Insights - OPKO Health, Inc. reported a significant decrease in total revenues for Q4 2025, amounting to $148.5 million, down from $183.6 million in Q4 2024, primarily due to the sale of certain BioReference assets [3][11] - The company experienced an operating loss of $38.3 million in Q4 2025 compared to a loss of $33.1 million in the same quarter of 2024 [3][16] - OPKO has entered into a research collaboration with Regeneron Pharmaceuticals, which could yield potential milestone payments exceeding $200 million for each program, with an overall potential value exceeding $1 billion [1][2] Business Highlights - A research collaboration with Regeneron Pharmaceuticals aims to develop multispecific antibodies using ModeX's MSTAR technology platform [1] - Merck completed a Phase 1 trial for an Epstein-Barr virus vaccine, with further studies planned [1] - MDX2003, a trispecific T-cell engager for leukemia and lymphoma, received approval for Phase 1 studies in Australia [1] - The partnership with Entera Bio has been expanded to advance a first-in-class oral long-acting PTH tablet for hypoparathyroidism [1][2] Financial Performance - Revenue from products in Q4 2025 was $43.7 million, an increase from $37.4 million in Q4 2024, driven by higher sales volumes in international operations [3][11] - Diagnostics revenue for Q4 2025 was $71.1 million, down from $103.1 million in the prior year, mainly due to the sale of BioReference assets [3][11] - Total costs and expenses increased to $88.0 million in Q4 2025 from $82.6 million in Q4 2024, attributed to higher research and development expenses and increased headcount [3][11] 2026 Financial Guidance - For Q1 2026, OPKO projects total revenues between $125 million and $140 million, with full-year revenues expected to range from $530 million to $560 million [4] - The company anticipates total costs and expenses for 2026 to be between $725 million and $750 million [4]